For example, in the diabetic mesenteric vascular bed, hyperglycemia-induced upregulation of Akt signaling was prevented by lapatinib, a dual inhibitor of EGFR and ErbB2 (Benter et al., 2015). Here, ERBB2 is linked to Hyperglycemia.